Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN

Slow Capital Inc. raised its holdings in Repligen Corporation (NASDAQ:RGEN) by 23.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,076 shares of the biotechnology company’s stock after acquiring an additional 8,511 shares during the period. Slow Capital Inc. owned about 0.08% of Repligen worth $5,892,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Repligen by 1.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after purchasing an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Repligen by 1.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock valued at $961,000 after buying an additional 80 shares in the last quarter. Drive Wealth Management LLC boosted its holdings in shares of Repligen by 2.5% in the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock valued at $472,000 after buying an additional 93 shares during the period. Hilltop National Bank boosted its holdings in shares of Repligen by 8.0% in the third quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 95 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of Repligen by 4.3% during the second quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 96 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $162.02 on Tuesday. The company has a market cap of $9.12 billion, a PE ratio of 8,105.05, a price-to-earnings-growth ratio of 2.94 and a beta of 1.12. The firm has a 50-day moving average of $163.01 and a 200-day moving average of $141.97. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The business had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same period last year, the business posted $0.43 EPS. Repligen’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. UBS Group boosted their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a report on Friday. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Canaccord Genuity Group upped their price target on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, Evercore ISI lifted their price objective on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $179.62.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 25,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total value of $3,922,000.00. Following the transaction, the director directly owned 100,743 shares in the company, valued at $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 49,657 shares of company stock worth $7,721,077. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.